---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-003600"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:46:53.211150+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study

## Summary
- UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.
- Obesity Phase 2: Co-admin bremelanotide + tirzepatide met primary endpoint with 4.4% weight loss vs 1.6% placebo (p<0.0001).
- Obesity: 40% of co-admin group achieved 5% weight loss (p<0.05); low-dose bremelanotide stopped weight regain post-tirzepatide.
- Next-gen MC4R long-acting peptides and oral small molecules; IND applications planned for 4Q25, clinical data 1H26.
- Licensing discussions for UC program advancing with multiple big pharma companies.

## SEC filing metadata
- accession: 0001654954-25-003600
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/0001654954-25-003600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-003600
- JSON: https://secwatch.observer/filing/0001654954-25-003600.json
- Plain text: https://secwatch.observer/filing/0001654954-25-003600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.